New drug combo aims to tackle resistant Hodgkin's lymphoma
NCT ID NCT05355051
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 28 times
Summary
This phase II trial tests whether combining two drugs—azacitidine and pembrolizumab—can help people with Hodgkin's lymphoma that has come back or stopped responding to treatment. About 24 participants will receive both drugs by IV. The main goal is to see how many patients respond to the combination.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN'S LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
azacitidine and pembrolizumab (given by IV)
What this could lead to
If successful, this combination could offer a new treatment option for patients whose Hodgkin's lymphoma has returned or not responded to prior therapy.
What could go wrong
This is a small, early-phase trial with only 24 participants, so results may not apply broadly. The combination may cause side effects and may not improve outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.